Skip to main content
. 2024 Jun 17;29(10):e1272–e1279. doi: 10.1093/oncolo/oyae123

Table 2.

The incidence of grades 3-5 toxicities in patients with low SMI and normal SMI.

All patients (n = 158) Low SMI (n = 30) Normal SMI (n = 128) P-value
Hematological AE 60 (38%) 19 (63.3%) 41 (32.0%) .001
 Anemia 36 (22.8%) 16 (53.3%) 20 (15.6%) <.001
 Neutropenia 33 (20.9%) 10 (33.3%) 23 (18%) .083
 Thrombocytopenia 12 (7.6%) 6 (20.0%) 6 (4.7%) .004
 Neutropenic fever 12 (7.6%) 5 (16.7%) 7 (5.5%) .037
Non-hematological AE 67 (42.4%) 20 (66.7%) 47 (36.7%) .003
 Hyponatremia 31 (19.6%) 10 (33.3%) 21 (16.4%) .044
 Hypokalemia 20 (12.7%) 7 (23.3%) 13 (10.2%) .067
 Hyperkalemia 2 (1.3%) 2 (6.7%) 0 (0%) .035
 Hypercalcemia 1 (0.6%) 1 (3.3%) 0 (0%) .190
 Creatinine increased 10 (6.3%) 3 (10.0%) 7 (5.5%) .402
 ALT increased 3 (1.9%) 0 (0%) 3 (2.3%) .662
 AST increased 4 (2.5%) 1 (3.3%) 3 (2.3%) 1.120
 Infection 21 (13.3%) 9 (30.0%) 12 (9.4%) .006
 Hand-foot syndrome 7 (4.4%) 4 (13.3%) 3 (2.3%) .009
 Nausea/vomiting 13 (8.2%) 4 (13.3%) 9 (7.0%) .258
 Diarrhea 15 (9.5%) 5 (16.7%) 10 (7.8%) .136

Bold values indicates significant differences.